Ibezapolstat Demonstrates 100% C Difficile Cure, No Recurrence in Small Study
Results on this investigational antibiotic in its phase 2A study were presented at the C Diff. Conference today.
Conference Coverage: New Challenges and Treatments for C Difficile Infection
Presentation highlights from the second and final day of the 9th Annual International C. diff Conference & Health Expo.
An End In Sight for C Difficile?
At the C Diff Foundation Conference, promising investigational modalities and therapies, as well as better treatment approaches are all being discussed in hopes of some real inroads being made in this field in the near future.
Is There Still Value in Prescribing Metronidazole for C Difficile Treatment?
Although no longer indicated as a first-line therapy, metronidazole still has therapeutic benefits and can serve patients in certain settings and circumstances.
Recurrent Infections and Other Challenges of C difficile Prevention
Highlights from some of this afternoon's presenters at the 9th Annual International C diff Conference & Health Expo.
Moving Forward: Investigational C Diff Vaccine, Therapeutics Headline Conference
Highlights from the morning session of the C Diff Foundation Conference included data about Pfizer's investigational vaccine, insights about Seres Therapeutics microbiome therapeutic, and a look at CDI incidence rates around COVID-19.
Empowering C Difficile Patients to Actively Fight Infection
Curtis Donskey, MD, discussed his efforts to encourage C. diff patients and providers to do their part to reduce infection and reinoculation.
The Role of Antimicrobial Stewardship in Deterring C Difficile
The development of these programs are being looked at for private practices in the community settings to try to create better prescribing practices and avoid the potential progression to health care associated infections.
C Diff Foundation Hosts Its Annual Conference
The organization is hosting its 9th Annual International C Diff Conference and Health EXPO on Thursday and Friday this week. The conference is virtual and free to the public.
Clostridioides Difficile Infection Symposium for Patients, Families, Caregivers
This event will be a free, virtual event in July with expert speakers and survivors.
Neotrope Announces C Diff Foundation as a 2018 JL Simmons NonProfit PR Grant Recipient
Neotrope announced the C diff Foundation as a recipient of the JL Simmons NonProfit PR Grant.
Changes in Recommendations for Diagnosis, Disease Severity, and Treatment of C difficile Infection in the 2017 Update to the IDSA/SHEA Clinical Practice Guidelines
The updated guidelines recommend targeting those with active infection and avoiding treatment of “carriers” of C difficile who are colonized but not symptomatic.
Nurses & Disinfection Practices: What Role Do They Play?
Barley Chironda, RPN, CIC, explains the role that nurses play in disinfection practices at health care facilities.
Cell Phones: Potential Vectors for C. diff?
Barley Chironda, RPN, CIC, infection control specialist at Clorox Healthcare, explains how cell phones and smart devices can potentially serve as a vector for C. diff.
Why Current Environmental Cleaning Practices Used in Hospitals Aren't Making the Cut
Barley Chironda, RPN, CIC, explains why current environmental disinfection practices aren’t making the cut.
C difficile Rates in the United Kingdom
Dr. Richard Vickers, discusses C. difficile rates in the United Kingdom.
High-Touch Points in Hospital Rooms That Harbor Pathogenic Bacteria
Barley Chironda, RPN, CIC, discusses different high-touch surfaces in hospital rooms that are known to harbor pathogenic bacteria.
The Escalating Problem & Cost of Antimicrobial Resistance
Glenn Tillotson, PhD, FIDSA, provides insight into the growing problem and cost of antimicrobial resistance.
What Are the Next Steps for Ridinilazole?
Dr. Richard Vickers, discusses what the next steps are for Summit Therapeutic’s ridinilazole.
Governmental Intervention Needed to Ensure Hospital Mattresses Get Cleaned Appropriately
Edmond Hooker, MD, DrPH, stresses that the FDA and the CDC need to intervene to ensure that hospital mattresses get cleaned appropriately.
Understanding What Motivates Health Care Works Crucial to Reducing C. diff Rates
Barley Chironda, RPN, CIC, stresses that understanding what motivates health care workers’ actions is crucial for reducing C. diff rates in hospitals.
How Do C. diff-Associated Costs Compare With Other HAIs?
Glenn Tillotson, PhD, FIDSA, explains how costs associated with Clostridium difficile compare with other problematic health care-associated infections.
Immunization Coverage: Why It's Harder to Cover Adults
Richard Haupt, MD, MPH, explains why it’s harder to cover adults rather than children when it comes to vaccination.
Study Finds Mattress Covers Cut Hospital CDI Rates in Half
Edmond Hooker, MD, DrPH, discusses a study that assessed the use of mattress covers in hospitals to cut down on CDI rates.
Motivating Health Care Workers to Wash Their Hands
Barley Chironda, RPN, CIC, discusses why some health care workers are not practicing good hand hygiene and ways to motivate them to do so.
How Does Ridinilazole Affect the Gut Microbiome?
Dr. Richard Vickers, explains how ridinilazole affected the gut microbiome in participants of a phase 2 study.
How Much Does It Cost to Develop New Drugs?
Glenn Tillotson, PhD, FIDSA, discusses the costs of drug development.
The C Diff Foundation Raises Clostridium difficile Infection (C difficile) Clinical Trial Awareness Worldwide
In the USA: Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention.
Contaminated Hospital Mattresses Act as Vector for Drug-Resistant Infections
Edmond Hooker, MD, DrPH, discusses how contaminated hospital mattresses act as a vector for spreading drug-resistant infections.
Ridinilazole Shows Superior Efficacy for Treatment of C. diff in Phase 2 Study
Dr. Richard Vickers, discusses how ridinilazole showed superior efficacy for the treatment of C. diff when compared with vancomycin in a phase 2 study.
2 Clarke Drive Cranbury, NJ 08512